Abivax Obefazimod Trial Data Published in The Lancet
Ticker: AAVXF · Form: 6-K · Filed: Jan 10, 2025 · CIK: 1956827
| Field | Detail |
|---|---|
| Company | Abivax S.A. (AAVXF) |
| Form Type | 6-K |
| Filed Date | Jan 10, 2025 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | bullish |
Sentiment: bullish
Topics: clinical-trial-results, publication, biotech, ulcerative-colitis
TL;DR
Abivax's ulcerative colitis drug obefazimod shows strong Phase 2b results in The Lancet, moving closer to Phase 3.
AI Summary
On January 9, 2025, Abivax SA announced the publication of positive Phase 2b clinical trial results for its lead drug candidate, obefazimod, in the journal 'The Lancet Gastroenterology & Hepatology'. The study demonstrated significant improvements in clinical remission rates for patients with moderate to severe ulcerative colitis. These results are expected to support the progression of obefazimod into Phase 3 clinical trials.
Why It Matters
The publication of positive Phase 2b data in a prestigious journal like The Lancet is a significant de-risking event for Abivax and could pave the way for pivotal Phase 3 trials, bringing their drug closer to potential market approval.
Risk Assessment
Risk Level: medium — While positive, the data is from a Phase 2b trial, and success in larger Phase 3 trials is not guaranteed, with regulatory approval still a significant hurdle.
Key Numbers
- Phase 2b — Clinical Trial Phase (Results published in The Lancet are from this stage of testing.)
Key Players & Entities
- Abivax SA (company) — Registrant and developer of obefazimod
- obefazimod (drug) — Lead drug candidate for ulcerative colitis
- The Lancet Gastroenterology & Hepatology (publication) — Journal where Phase 2b results were published
- January 9, 2025 (date) — Date of press release and publication announcement
- Phase 2b (clinical_trial_phase) — Stage of the clinical trial with positive results
- ulcerative colitis (disease) — Condition being treated by obefazimod
FAQ
What specific clinical outcomes were reported for obefazimod in the Phase 2b trial?
The press release, incorporated by reference, likely details specific improvements in clinical remission rates for patients with moderate to severe ulcerative colitis, as indicated by the summary.
When were the Phase 2b results published?
The results were published on January 9, 2025, in 'The Lancet Gastroenterology & Hepatology'.
What is the next planned step for obefazimod's development?
The positive Phase 2b results are expected to support the progression of obefazimod into Phase 3 clinical trials.
What is the file number for Abivax SA's registration statement on Form F-3?
The file number for Abivax SA's registration statement on Form F-3 is 333-283336.
What is the primary indication for Abivax's drug candidate, obefazimod?
Obefazimod is being developed for the treatment of ulcerative colitis.
Filing Stats: 247 words · 1 min read · ~1 pages · Grade level 13.1 · Accepted 2025-01-10 09:04:55
Filing Documents
- d905529d6k.htm (6-K) — 9KB
- d905529dex991.htm (EX-99.1) — 16KB
- g905529g0109225101395.jpg (GRAPHIC) — 3KB
- 0001193125-25-004163.txt ( ) — 31KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Abivax SA (Registrant) Date: January 10, 2025 /s/ Marc de Garidel Marc de Garidel Chief Executive Officer